MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src

Journal of Cell Science

Volumn 123, Issue 23, 2010, Pages 4182-4193

  Eisenach, Patricia A ^a   Roghi, Christian ^a   Fogarasi, Marton ^a   Murphy, Gillian ^a   English, William R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

KDR; MT1 MMP; Src; VEGF A; VEGFR 2

Indexed keywords

HEMOPEXIN; MATRIX METALLOPROTEINASE 14; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CATALYSIS; CELL STRAIN MCF 7; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; TRANSCRIPTION REGULATION;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; HUMANS; MATRIX METALLOPROTEINASE 14; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS PP60(C-SRC); VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 78649734507     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.062711     Document Type: Article

References (77)

1. Atkinson, S. J., Roghi, C. and Murphy, G. (2006). MT1-MMP hemopexin domain exchange with MT4-MMP blocks enzyme maturation and trafficking to the plasma membrane in MCF7 cells. Biochem. J. 398, 15-22.
2. Burrage, P. S., Mix, K. S. and Brinckerhoff, C. E. (2006). Matrix metalloproteinases: role in arthritis. Front. Biosci. 11, 529-543.
3. Chou, M. T., Wang, J. and Fujita, D. J. (2002). Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells. BMC Biochem. 3, 32.
4. Crabbe, T., Willenbrock, F., Eaton, D., Hynds, P., Carne, A. F., Murphy, G. and Docherty, A. J. (1992). Biochemical characterization of matrilysin. Activation conforms to the stepwise mechanisms proposed for other matrix metalloproteinases. Biochemistry 31, 8500-8507.
5. D'Alessio, S., Ferrari, G., Cinnante, K., Scheerer, W., Galloway, A. C., Roses, D. F., Rozanov, D. V., Remacle, A. G., Oh, E. S., Shiryaev, S. A. et al. (2008). Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism. J. Biol. Chem. 283, 87-99.
6. d'Ortho, M. P., Will, H., Atkinson, S., Butler, G., Messent, A., Gavrilovic, J., Smith, B., Timpl, R., Zardi, L. and Murphy, G. (1997). Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur. J. Biochem. 250, 751-757.
7. d'Ortho, M. P., Stanton, H., Butler, M., Atkinson, S. J., Murphy, G. and Hembry, R. M. (1998). MT1-MMP on the cell surface causes focal degradation of gelatin films. FEBS Lett. 421, 159-164.
8. Dean, R. A., Butler, G. S., Hamma-Kourbali, Y., Delbe, J., Brigstock, D. R., Courty, J. and Overall, C. M. (2007). Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol. Cell. Biol. 27, 8454-8465.
9. Deryugina, E. I., Ratnikov, B. I., Postnova, T. I., Rozanov, D. V. and Strongin, A. Y. (2002a). Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J. Biol. Chem. 277, 9749-9756.
10. Deryugina, E. I., Soroceanu, L. and Strongin, A. Y. (2002b). Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res. 62, 580-588.
11. Devy, L., Huang, L., Naa, L., Yanamandra, N., Pieters, H., Frans, N., Chang, E., Tao, Q., Vanhove, M., Lejeune, A. et al. (2009). Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 69, 1517-1526.
12. Ebos, J. M., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G. and Kerbel, R. S. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239.
13. Egeblad, M. and Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174.
14. Endo, K., Takino, T., Miyamori, H., Kinsen, H., Yoshizaki, T., Furukawa, M. and Sato, H. (2003). Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J. Biol. Chem. 278, 40764-40770.
15. Figueira, R. C., Gomes, L. R., Neto, J. S., Silva, F. C., Silva, I. D. and Sogayar, M. C. (2009). Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 9, 20.
16. Fosang, A. J., Last, K., Fujii, Y., Seiki, M. and Okada, Y. (1998). Membrane-type 1 MMP (MMP-14) cleaves at three sites in the aggrecan interglobular domain. FEBS Lett. 430, 186-190.
17. Freudenberg, J. A. and Chen, W. T. (2007). Induction of Smad1 by MT1-MMP contributes to tumor growth. Int. J. Cancer 121, 966-977.
18. Gampel, A., Moss, L., Jones, M. C., Brunton, V., Norman, J. C. and Mellor, H. (2006). VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. Blood 108, 2624-2631.
19. Gingras, D., Bousquet-Gagnon, N., Langlois, S., Lachambre, M. P., Annabi, B. and Beliveau, R. (2001). Activation of the extracellular signal-regulated protein kinase (ERK) cascade by membrane-type-1 matrix metalloproteinase (MT1-MMP). FEBS Lett. 507, 231-236.
20. Greenberg, J. I., Shields, D. J., Barillas, S. G., Acevedo, L. M., Murphy, E., Huang, J., Scheppke, L., Stockmann, C., Johnson, R. S., Angle, N. et al. (2008). A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456, 809-813.
21. Hashimoto, G., Inoki, I., Fujii, Y., Aoki, T., Ikeda, E. and Okada, Y. (2002). Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J. Biol. Chem. 277, 36288-36295.
22. Holmbeck, K., Bianco, P., Caterina, J., Yamada, S., Kromer, M., Kuznetsov, S. A., Mankani, M., Robey, P. G., Poole, A. R., Pidoux, I. et al. (1999). MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99, 81-92.
23. Holmqvist, K., Cross, M. J., Rolny, C., Hagerkvist, R., Rahimi, N., Matsumoto, T., Claesson-Welsh, L. and Welsh, M. (2004). The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J. Biol. Chem. 279, 22267-22275.
24. Hotary, K., Allen, E., Punturieri, A., Yana, I. and Weiss, S. J. (2000). Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J. Cell Biol. 149, 1309-1323.
25. Hotary, K. B., Allen, E. D., Brooks, P. C., Datta, N. S., Long, M. W. and Weiss, S. J. (2003). Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114, 33-45.
26. Inoki, I., Shiomi, T., Hashimoto, G., Enomoto, H., Nakamura, H., Makino, K., Ikeda, E., Takata, S., Kobayashi, K. and Okada, Y. (2002). Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 16, 219-221.
27. Janssens, S. and Lijnen, H. R. (2006). What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? Cardiovasc. Res. 69, 585-594.
28. Jiang, W. G., Davies, G., Martin, T. A., Parr, C., Watkins, G., Mason, M. D. and Mansel, R. E. (2006). Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int. J. Mol. Med. 17, 583-590.
29. Kajita, M., Itoh, Y., Chiba, T., Mori, H., Okada, A., Kinoh, H. and Seiki, M. (2001). Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Biol. 153, 893-904.
30. Kim, H. J., Park, C. I., Park, B. W., Lee, H. D. and Jung, W. H. (2006). Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med. J. 47, 333-342.
31. Koshikawa, N., Giannelli, G., Cirulli, V., Miyazaki, K. and Quaranta, V. (2000). Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J. Cell Biol. 148, 615-624.
32. Kroll, J. and Waltenberger, J. (1997). The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J. Biol. Chem. 272, 32521-32527.
33. Krubasik, D., Eisenach, P. A., Kunz-Schughart, L. A., Murphy, G. and English, W. R. (2008). Granulocyte-macrophage colony stimulating factor induces endothelial capillary formation through induction of membrane-type 1 matrix metalloproteinase expression in vitro. Int. J. Cancer 122, 1261-1272.
34. Labrecque, L., Royal, I., Surprenant, D. S., Patterson, C., Gingras, D. and Beliveau, R. (2003). Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol. Biol. Cell 14, 334-347.
35. Labrecque, L., Nyalendo, C., Langlois, S., Durocher, Y., Roghi, C., Murphy, G., Gingras, D. and Beliveau, R. (2004). Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J. Biol. Chem. 279, 52132-52140.
36. Lafleur, M. A., Handsley, M. M., Knauper, V., Murphy, G. and Edwards, D. R. (2002). Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J. Cell Sci. 115, 3427-3438.
37. Lehti, K., Lohi, J., Valtanen, H. and Keski-Oja, J. (1998). Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem. J. 334, 345-353.
38. Lehti, K., Allen, E., Birkedal-Hansen, H., Holmbeck, K., Miyake, Y., Chun, T. H. and Weiss, S. J. (2005). An MT1-MMP-PDGF receptor-beta axis regulates mural cell investment of the microvasculature. Genes Dev. 19, 979-991.
39. Linderholm, B. K., Lindh, B., Beckman, L., Erlanson, M., Edin, K., Travelin, B., Bergh, J., Grankvist, K. and Henriksson, R. (2003). Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin. Breast Cancer 4, 340-347.
40. Lopez-Otin, C. and Matrisian, L. M. (2007). Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 7, 800-808.
41. Ludwig, T., Theissen, S. M., Morton, M. J. and Caplan, M. J. (2008). The cytoplasmic tail dileucine motif LL572 determines the glycosylation pattern of membrane-type 1 matrix metalloproteinase. J. Biol. Chem. 283, 35410-35418.
42. Matsumoto, T., Bohman, S., Dixelius, J., Berge, T., Dimberg, A., Magnusson, P., Wang, L., Wikner, C., Qi, J. H., Wernstedt, C. et al. (2005). VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J. 24, 2342-2353.
43. Mohamed, M. M. and Sloane, B. F. (2006). Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 6, 764-775.
44. Mori, H., Tomari, T., Koshikawa, N., Kajita, M., Itoh, Y., Sato, H., Tojo, H., Yana, I. and Seiki, M. (2002). CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J. 21, 3949-3959.
45. Munaut, C., Noel, A., Hougrand, O., Foidart, J. M., Boniver, J. and Deprez, M. (2003). Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int. J. Cancer 106, 848-855.
46. Murphy, G. and Willenbrock, F. (1995). Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol. 248, 496-510.
47. Murphy, G., Willenbrock, F., Ward, R. V., Cockett, M. I., Eaton, D. and Docherty, A. J. (1992). The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem. J. 283, 637-641.
48. Noel, A., Jost, M. and Maquoi, E. (2008). Matrix metalloproteinases at cancer tumor-host interface. Semin. Cell Dev. Biol. 19, 52-60.
49. Nomura, H., Sato, H., Seiki, M., Mai, M. and Okada, Y. (1995). Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res. 55, 3263-3266.
50. Nyalendo, C., Michaud, M., Beaulieu, E., Roghi, C., Murphy, G., Gingras, D. and Beliveau, R. (2007). Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573, role in endothelial and tumor cell migration. J. Biol. Chem. 282, 15690-15699.
51. Ohuchi, E., Imai, K., Fujii, Y., Sato, H., Seiki, M. and Okada, Y. (1997). Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J. Biol. Chem. 272, 2446-2451.
52. Olsson, A. K., Dimberg, A., Kreuger, J. and Claesson-Welsh, L. (2006). VEGF receptor signalling-in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359-371.
53. Overall, C. M. and Kleifeld, O. (2006). Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6, 227-239.
54. Paez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Vinals, F., Inoue, M., Bergers, G., Hanahan, D. and Casanovas, O. (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231.
55. Remacle, A., Murphy, G. and Roghi, C. (2003). Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. J. Cell Sci. 116, 3905-3916.
56. Rozanov, D. V., Savinov, A. Y., Williams, R., Liu, K., Golubkov, V. S., Krajewski, S. and Strongin, A. Y. (2008). Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer. Cancer Res. 68, 4086-4096.
57. Saeb-Parsy, K., Veerakumarasivam, A., Wallard, M. J., Thorne, N., Kawano, Y., Murphy, G., Neal, D. E., Mills, I. G. and Kelly, J. D. (2008). MT1-MMP regulates urothelial cell invasion via transcriptional regulation of Dickkopf-3. Br. J. Cancer 99, 663-669.
58. Sithu, S. D., English, W. R., Olson, P., Krubasik, D., Baker, A. H., Murphy, G. and D'Souza, S. E. (2007). Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration. J. Biol. Chem. 282, 25010-25019.
59. Soldi, R., Mitola, S., Strasly, M., Defilippi, P., Tarone, G. and Bussolino, F. (1999). Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 18, 882-892.
60. Soulie, P., Carrozzino, F., Pepper, M. S., Strongin, A. Y., Poupon, M. F. and Montesano, R. (2005). Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells. Oncogene 24, 1689-1697.
61. Sounni, N. E., Devy, L., Hajitou, A., Frankenne, F., Munaut, C., Gilles, C., Deroanne, C., Thompson, E. W., Foidart, J. M. and Noel, A. (2002). MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J. 16, 555-564.
62. Sounni, N. E., Roghi, C., Chabottaux, V., Janssen, M., Munaut, C., Maquoi, E., Galvez, B. G., Gilles, C., Frankenne, F., Murphy, G. et al. (2004). Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J. Biol. Chem. 279, 13564-13574.
63. Stanton, H., Gavrilovic, J., Atkinson, S. J., d'Ortho, M. P., Yamada, K. M., Zardi, L. and Murphy, G. (1998). The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J. Cell Sci. 111, 2789-2798.
64. Takino, T., Miyamori, H., Kawaguchi, N., Uekita, T., Seiki, M. and Sato, H. (2003). Tetraspanin CD63 promotes targeting and lysosomal proteolysis of membrane-type 1 matrix metalloproteinase. Biochem. Biophys. Res. Commun. 304, 160-166.
65. Tam, E. M., Morrison, C. J., Wu, Y. I., Stack, M. S. and Overall, C. M. (2004). Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc. Natl. Acad. Sci. USA 101, 6917-6922.
66. Tokuraku, M., Sato, H., Murakami, S., Okada, Y., Watanabe, Y. and Seiki, M. (1995). Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int. J. Cancer 64, 355-359.
67. Toth, M., Hernandez-Barrantes, S., Osenkowski, P., Bernardo, M. M., Gervasi, D. C., Shimura, Y., Meroueh, O., Kotra, L. P., Galvez, B. G., Arroyo, A. G. et al. (2002). Complex pattern of membrane type 1 matrix metalloproteinase shedding. Regulation by autocatalytic cells surface inactivation of active enzyme. J. Biol. Chem. 277, 26340-26350.
68. Uekita, T., Itoh, Y., Yana, I., Ohno, H. and Seiki, M. (2001). Cytoplasmic tail-dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity. J. Cell Biol. 155, 1345-1356.
69. Ueno, H., Nakamura, H., Inoue, M., Imai, K., Noguchi, M., Sato, H., Seiki, M. and Okada, Y. (1997). Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res. 57, 2055-2060.
70. Ulici, V., Hoenselaar, K. D., Agoston, H., McErlain, D. D., Umoh, J., Chakrabarti, S., Holdsworth, D. W. and Beier, F. (2009). The role of Akt1 in terminal stages of endochondral bone formation: angiogenesis and ossification. Bone 45, 1133-1145.
71. Warner, A. J., Lopez-Dee, J., Knight, E. L., Feramisco, J. R. and Prigent, S. A. (2000). The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells. Biochem. J. 347, 501-509.
72. Wolf, K. and Friedl, P. (2009). Mapping proteolytic cancer cell-extracellular matrix interfaces. Clin. Exp. Metastasis 26, 289-298.
73. Yamaoka-Tojo, M., Ushio-Fukai, M., Hilenski, L., Dikalov, S. I., Chen, Y. E., Tojo, T., Fukai, T., Fujimoto, M., Patrushev, N. A., Wang, N. et al. (2004). IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species-dependent endothelial migration and proliferation. Circ. Res. 95, 276-283.
74. Yanez-Mo, M., Barreiro, O., Gonzalo, P., Batista, A., Megias, D., Genis, L., Sachs, N., Sala-Valdes, M., Alonso, M. A., Montoya, M. C. et al. (2008). MT1-MMP collagenolytic activity is regulated through association with tetraspanin CD151 in primary endothelial cells. Blood 112, 3217-3226.
75. Yoshizaki, T., Sato, H., Maruyama, Y., Murono, S., Furukawa, M., Park, C. S. and Seiki, M. (1997). Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma. Cancer 79, 139-144.
76. Zhang, W., Matrisian, L. M., Holmbeck, K., Vick, C. C. and Rosenthal, E. L. (2006). Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 6, 52.
77. Zhou, Z., Apte, S. S., Soininen, R., Cao, R., Baaklini, G. Y., Rauser, R. W., Wang, J., Cao, Y. and Tryggvason, K. (2000). Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci. USA 97, 4052-4057.